After pre-announcing that its full-year revenue would come in below its original guidance, Eli Lilly (NYSE: LLY) announced ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

A new study examines how cost, side effects and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Nearly 2 in 3 people who sought to lose weight quit popular weight loss and diabetes drugs such as Ozempic or Victoza within one year, according to a new study. About 65% of those without diabetes ...

Acting as GLP-1R agonists (GLP-1RAs), the drugs promote feelings of satiety and fullness, aiding weight loss among patients who are overweight or obese. Aside from their success for type 2 diabetes ...

A new AP-NORC poll reveals that while most Americans support weight-loss drugs like Ozempic and Wegovy for adults with obesity, they are divided on their use for teens. About half of adults favor ...

with millions turning to medications like Ozempic and Wegovy in hopes of shedding excess weight and managing diabetes. These drugs, classified as GLP-1 receptor agonists, promise more than just ...

Puhan, and Henock G. Yebyo. “GLP-1 Receptor Agonists for Weight Reduction in People Living with Obesity but without Diabetes: A Living Benefit-Harm Modelling Study.” eClinicalMedicine (July 2024).